Breast JournalPub Date : 2026-04-11DOI: 10.1155/tbj/6196988
S. David Nathanson, Shravan Leonard-Murali, Jenny Bui, Dhananjay A. Chitale, Jessica Bensenhaver, Theresa Schwartz, Lindsay Petersen, Kylie Springer, Patricia Baker, Laura L. Susick
{"title":"Selected Pathological Criteria That Predict Low Rates of Axillary Lymph Node Metastases Regardless of Patient Age: A Single Institution Study","authors":"S. David Nathanson, Shravan Leonard-Murali, Jenny Bui, Dhananjay A. Chitale, Jessica Bensenhaver, Theresa Schwartz, Lindsay Petersen, Kylie Springer, Patricia Baker, Laura L. Susick","doi":"10.1155/tbj/6196988","DOIUrl":"10.1155/tbj/6196988","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Omission of sentinel node biopsy is increasingly offered to selected older women with cN0 low-risk breast cancer (BC). We hypothesized that some younger women might exhibit a low enough incidence of lymph node metastases to possibly justify excluding axillary surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We statistically analyzed, using parametric and nonparametric tests as appropriate, multiple demographic and clinicopathologic variables in cT1-2 N0 M0 BC patients of all ages undergoing axillary LN excisional surgery from a long-term, prospectively maintained database.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients with (816) and without (3617) LN metastases were compared. Although older patients were significantly (<i>p</i> < 0.0001) less likely to have LN metastases compared to younger patients, 3/61 (4.92%) of those < 50 years old with grade 1 tumors ≤ 1 cm in size (T1a and b) and no lymphovascular invasion had LN metastases compared to 30/504 (5.95%) ≥ 50. Patients aged 50 or older with Grade 2/3, < 1 cm, LVI-negative tumors had only 53/774 (6.85%) LN positive, compared to 19/131 (14.5%) in women < 50 with the same pathology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Women with grade 1, ≤ 1 cm invasive BCs, and no LVI had < 6% incidence of LN metastases regardless of age. Instead of excluding younger women from axillary node surgery de-escalation strategies, this study suggests that any woman with a tumor size ≤ 1 cm, Grade 1, and no LVI could be evaluated in prospective studies whose objective is to safely avoid axillary LN surgery.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13069968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147663120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast JournalPub Date : 2026-04-08DOI: 10.1155/tbj/9970072
Maria Eleni Hatzipanagiotou, Verena Tannert, Michael Gerken, Miriam Pigerl, Sophie Räpple, Jonas Roth, Monika Klinkhammer-Schalke, Olaf Ortmann, Stephan Seitz
{"title":"Treatment Regimens and Response Rates in Early TNBC: A Review of Real-World Practice in the Second Decade of the 21st Century","authors":"Maria Eleni Hatzipanagiotou, Verena Tannert, Michael Gerken, Miriam Pigerl, Sophie Räpple, Jonas Roth, Monika Klinkhammer-Schalke, Olaf Ortmann, Stephan Seitz","doi":"10.1155/tbj/9970072","DOIUrl":"10.1155/tbj/9970072","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Real-world evidence on the treatment of early triple-negative breast cancer (TNBC) remains limited. This study provides an overview of neoadjuvant chemotherapy (NACT) regimens used in the 2010s of the 21<sup>st</sup> century, analyzing patient outcomes and treatment patterns based on real-world data from a large population-based cancer registry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this retrospective, noninterventional, single-center study, we analyzed data from TNBC patients diagnosed between January 1, 2010, and December 31, 2018, registered in the Tumor Centre Regensburg. Data included demographics, pathology, treatment regimen, recurrence, and survival, with follow-up extending to December 2023. Outcomes included pathologic complete response (pCR), overall survival (OS), and recurrence-free survival (RFS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 319 patients were included. Among them, 132 patients (41.4%) received NACT with epirubicin/cyclophosphamide (EC) and paclitaxel (EC-T), 74 patients (23.2%) received NACT with EC-T and platinum (EC-P/T), and 22 patients (6.9%) received NACT with EC-P/nab-paclitaxel (EC-P/nabP). Other NACT protocols were administered in 91 (28.5%) patients. A pCR occurred in 49.8% of NACT patients, with a 37.1% rate in the subgroup without platinum. Addition of platinum significantly increased the pCR rate to 54.1% compared to EC-T (odds ratio [OR] 3.476, 95% confidence interval [CI] 1.655–7.300, <i>p</i> = 0.001). EC-P/nabP led to a significant increase in pCR rate to 77.3% (OR 8.767, 95% CI 2.421–31.744, <i>p</i> < 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The evidence from clinical trials was quickly incorporated into clinical practice, leading to higher pCR rates and benefits for patients. In the next step, the implementation of immune checkpoint inhibitors in real-world practice will be analyzed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13059670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147635227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast JournalPub Date : 2026-04-04DOI: 10.1155/tbj/8459253
Liane N. Obaid, Janice S. Zhang, Grace Y. Lee, Fardeen Bhimani, Susan L. Jao, Carolyn Rachofsky, Lesley G. Coe, Arianna Cavalli, Michelle Ki, Juan Lin, Anjuli Gupta, Sheldon Feldman, Maureen McEvoy
{"title":"The Impact of Socioeconomic Factors and Racial Disparities on Complications in Breast Conservation Surgery: A Single-Institution Retrospective Cohort Study","authors":"Liane N. Obaid, Janice S. Zhang, Grace Y. Lee, Fardeen Bhimani, Susan L. Jao, Carolyn Rachofsky, Lesley G. Coe, Arianna Cavalli, Michelle Ki, Juan Lin, Anjuli Gupta, Sheldon Feldman, Maureen McEvoy","doi":"10.1155/tbj/8459253","DOIUrl":"10.1155/tbj/8459253","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast conservation surgery (BCS) is considered to be a low-morbidity procedure; however, postoperative complications may adversely affect the quality of life of breast cancer survivors. Social determinants of health have previously been shown to impact postoperative outcomes in various other medical conditions. However, there is a paucity of literature that comprehensively examines the social determinants that impact BCS complications or how race influences specific surgical outcomes. This study thus seeks to address this gap by analyzing the impact of these factors within our diverse patient population in the Bronx.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective chart review was conducted that examined patients who underwent BCS between January 2016 and December 2022 at a single institution. Patient information, such as comorbidities, Distressed Communities Index (DCI), BMI, race, insurance status, age, pathology, surgery details, adjuvant therapy, and complications, was collected. Univariate and multivariate analyses were utilized to determine the relationship between these variables and postoperative complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 627 patients were included in the study. Of these patients, 512 (81.5%) were either Hispanic or African American, 46 patients (7.3%) were White, and 69 (11%) belonged to other races. There was a delay in 37 (6.2%) patients receiving adjuvant therapy. Our study found that higher DCI quintile and higher BMI were associated with a statistically significant increase in overall complication rate (<i>p</i> = 0.044, <i>p</i> = 0.05, respectively). Race had an association with persistent pain (<i>p</i> = 0.003). Former smokers (OR = 3.44, 95% CI [1.419, 8.34], <i>p</i> = 0.0062), hypertensive patients (OR = 3.846, 95% CI [1.13, 13.12], <i>p</i> = 0.0314), and patients who received adjuvant chemotherapy (OR = 2.756, 95% CI [1.117, 6.801], <i>p</i> = 0.0278) had higher odds of developing any complication. Patients who developed any complication were more likely to have a delay in adjuvant therapy than patients who did not have complications (OR = 6.452, CI [2.696, 15.44], <i>p</i> < 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>BCS is generally a safe procedure with minimal complications; however, patient-specific factors are associated with increased complication rates which can lead to delays in adjuvant therapy. Future studies with larger sample sizes are needed to adequately compare outcomes among minority racial groups to a lar","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147617166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
